News

Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01

A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment for vascular dementia Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with Firefly Neuroscience, Inc. (NASDAQ: AIFF) ("Firefly"), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Hemostemix and Firefly will study brain wave activity in up to 100 patients before and after treatment with ACP-01 at baseline, 3-months, and 6-months post-treatment (the "Phase 1").

03/06/2025

Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million

Extends cash runway well into mid-2026; no new/replacement warrants issued Extends cash runway well into mid-2026; no new/replacement warrants issued

02/21/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is (AIFF) a buy, sell, or hold?

(AIFF) can sell. Click on Rating Page for detail.

What is 's stock price?

The price of (AIFF) is 3.2 and it was updated on 2025-04-26 01:54:56.

Is (AIFF) overvalued or undervalued?

Currently (AIFF) is in undervalued.

News

From:

To:

News
Firefly Neuroscience Accepted into NVIDIA Connect Program Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform Tue, Feb. 11, 2025
Firefly Neuroscience Congratulates Scientific Advisor, Dr. Christopher Wilson, Recipient of Prestigious UW Faculty of Engineering Award for Work on Superconducting Quantum Electronics - University of Waterloo's Faculty of Engineering Recognizes Dr. Wilson with Faculty Research Excellence Award - - Esteemed researchers and engineers like Dr. Wilson are currently helping Firefly lay the groundwork for an exciting new brain model initiative to be revealed soon - KENMORE, N.Y., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to congratulate Christopher Wilson, PhD, on being recognized by the University of Waterloo's (“UW”) Faculty of Engineering for his significant contributions to research and scholarship. Fri, Feb. 07, 2025
Crude Oil Down 1%; Firefly Neuroscience Shares Spike Higher U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Tuesday. Tue, Jan. 14, 2025
Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer's patients Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer's patients Tue, Jan. 14, 2025
Firefly Neuroscience Closes on Financing of up to $12.4 Million TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the closing of up to $12.4 million consisting of $2.4 million up front in the form of senior secured convertible notes at $3.00 per share, subject to adjustment, and an equity line of credit (the “ELOC”) for up to $10 million. The proceeds from these financings will be used for growth, commercialization of its FDA-510(k) cleared Brain Network Analytics (BNA™) technology, and general working capital purposes. Tue, Dec. 31, 2024

Press Releases

StockPrice Release
Hemostemix and firefly neuroscience's brain network analytics (bna(tm)) engage to complete phase 1 vascular dementia clinical trial of acp-01 03/06/2025
Firefly neuroscience announces exercise of warrants for total proceeds of $8.8 million 02/21/2025
Firefly neuroscience accepted into nvidia connect program 02/11/2025
Firefly neuroscience congratulates scientific advisor, dr. christopher wilson, recipient of prestigious uw faculty of engineering award for work on superconducting quantum electronics 02/07/2025
Firefly neuroscience discovers breakthrough cognitive brain age biomarker using its fda-cleared bna™ platform 01/14/2025
Firefly neuroscience closes on financing of up to $12.4 million 12/31/2024
Firefly neuroscience reports third quarter 2024 results and provides stockholder update 11/14/2024
Firefly neuroscience to participate in the 8th annual florida capital event 11/06/2024
Firefly neuroscience announces inducement grant under nasdaq listing rule 5635(c)(4) 10/25/2024
Firefly neuroscience collaborates with bright minds biosciences to analyze the data from its positive phase 1 study using its artificial intelligence, fda-cleared bna™ technology 10/16/2024
Firefly neuroscience to participate in upcoming october investor conferences 10/11/2024
Firefly neuroscience announces partnership with zeto to integrate and distribute its bna™ technology with zeto's fda-cleared eeg device platform 09/10/2024
Firefly neuroscience ceo jon olsen to present at h.c. wainwright's 26th annual global investment conference september 9-11 08/26/2024
Firefly neuroscience, an ai-driven brain health company, to host shareholder update call on september 4th 08/22/2024
Firefly neuroscience forms strategic partnership with neurology consultants of dallas (ncd) to enhance early detection efforts and disease management for patients with cognitive disorders 08/21/2024

More Headlines

News
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company's dual go-to-market strategy TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced its financial results for the third quarter ended September 30, 2024, and provided a stockholder update. Firefly is dedicated to improving outcomes for people suffering with brain health illnesses by bringing objective measurement of brain activity to the front lines of healthcare. 11/14/2024
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the Capital Event Management Conference being held at the JW Marriott Miami in Aventura, Florida on November 22-24, 2024. 11/06/2024
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that the Board of Directors of Firefly granted 557,885 restricted shares (the “Shares”) as an inducement grant to David Johnson, the Company's Executive Chairman, pursuant to that certain Employment Agreement (the “Agreement”), by and between the Company and Mr. Johnson. The Shares were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of the Agreement and the Company's 2024 Long-Term Incentive Plan. 10/25/2024
Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology During the Phase 1 study, subjects utilized EEG headsets provided by Firefly partner, Zeto, after which the data was analyzed using Firefly's advanced AI BNA technology analysis platform During the Phase 1 study, subjects utilized EEG headsets provided by Firefly partner, Zeto, after which the data was analyzed using Firefly's advanced AI BNA technology analysis platform 10/16/2024
Firefly Neuroscience to Participate in Upcoming October Investor Conferences TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the following October 2024 investor conferences: 10/11/2024
Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform Partnership will expand Firefly's FDA Cleared BNA™ technology to more hospitals and physician offices Partnership will expand Firefly's FDA Cleared BNA™ technology to more hospitals and physician offices 09/10/2024
Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright's 26th Annual Global Investment Conference September 9-11 TORONTO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that its Chief Executive Officer, Jon Olsen, will present at H.C. Wainwright's 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 9-11, 2024. 08/26/2024
Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders, today announced management will host a shareholder update call on Wednesday, September 4, 2024 at 5:00 PM Eastern Time. 08/22/2024
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders NCD Will Integrate Firefly's BNA Technology into its Patient Management Protocols for Enhanced Brain Function Insights and Improved Patient Outcomes NCD Will Integrate Firefly's BNA Technology into its Patient Management Protocols for Enhanced Brain Function Insights and Improved Patient Outcomes 08/21/2024

Unlock

AIFF Ratings Summary

AIFF Quant Ranking

Is (AIFF) a buy, sell, or hold?

What is 's stock price?

Is (AIFF) overvalued or undervalued?

Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update

Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event

Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology

Firefly Neuroscience to Participate in Upcoming October Investor Conferences

Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform

Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright's 26th Annual Global Investment Conference September 9-11

Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th

Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth

Performance

Momentum

Profitability

Risk

Ownership

Debt